Study: Semaglutide Could Be Made for $3 Monthly in Canada

A new study published in The Guardian reveals that semaglutide, the active ingredient in drugs like Ozempic and Wegovy, could be manufactured for as little as $3 per month, highlighting the vast gap between production costs and current retail prices in Canada.

Manufacturing Cost Analysis

The research findings come at a crucial time for Canada, which became the first country where Novo Nordisk's semaglutide patent expired on January 4, 2026. The study's cost estimates suggest that generic manufacturers could potentially produce semaglutide at a fraction of current brand-name pricing once Ozempic generics enter the Canadian market.

Current retail prices for semaglutide medications in Canada range from approximately $300 to $400 per month depending on the strength and pharmacy. The $3 manufacturing cost estimate represents less than 1% of these retail prices, indicating substantial potential for price reductions.

Canadian Generic Market Implications

Health Canada is currently reviewing nine generic semaglutide applications from various manufacturers including Sandoz, Apotex, and Teva. The low manufacturing costs identified in the study could enable these generic producers to offer significantly reduced pricing while maintaining healthy profit margins.

Several factors influence the final retail pricing beyond manufacturing costs:

• Research and development investments
• Regulatory approval expenses
• Distribution and pharmacy markups
• Marketing and administrative costs

Industry experts note that even accounting for these additional costs, the study's findings suggest substantial room for price competition once generics launch.

Global Context and Canadian Advantage

The research highlighted that Canada's unique position as the only country with expired semaglutide patents makes it a reference market for global generic development. Companies like Aspen Pharmacare have indicated plans to use Canada as a launching point for broader international generic distribution.

The study's cost analysis applies to both Ozempic and Wegovy formulations, as they contain the same active ingredient at different concentrations. This could potentially benefit patients using either medication for approved indications.

Timeline for Generic Availability

Despite the patent expiration and low manufacturing costs, experts caution that generic semaglutide availability in Canadian pharmacies remains several months away. Health Canada's approval process for the nine pending applications is expected to continue through the third quarter of 2026.

Pharmacies including Shoppers Drug Mart, Costco, and Walmart are preparing for eventual generic launches, though specific pricing strategies have not been announced. The generic semaglutide tracker continues monitoring approval progress and expected launch dates.

Market Competition Effects

The study's cost revelations come alongside recent price reductions from established manufacturers. Eli Lilly recently cut Mounjaro and Zepbound prices by 20% in Canada, while Novo Nordisk announced plans for up to 50% price reductions on Ozempic and Wegovy by 2027.

These proactive price cuts by brand manufacturers suggest anticipation of significant generic competition based on the low manufacturing costs now documented in peer-reviewed research. Canadian patients may benefit from this competitive pressure even before generic versions reach pharmacy shelves.

Insurance Coverage Considerations

The potential for dramatically lower-cost semaglutide could impact insurance coverage decisions across Canada. Many private and public drug plans currently have restrictions or require prior authorization for these medications due to high costs.

Lower generic pricing might enable broader coverage and reduced patient co-payments. The insurance coverage checker will be updated as new generic pricing and coverage policies are announced.

This article is for informational purposes only and does not constitute medical advice.